🇺🇸

US SEC Filing Intelligence

· daily

HHS & Healthcare Contracts Intelligence — April 08, 2026

HHS awarded $300,921,779 across three contracts in the HHS & Healthcare stream, with 0/3 defense-related, focusing on BARDA-funded biotech R&D for biothreat and antibiotic-resistant pathogens. Dominant theme is civilian biothreat preparedness via long-duration BARDA contracts to Shionogi Inc ($119M obligation) and Vedanta Biosciences ($79M obligation), signaling multi-year revenue potential in NAICS 541714 biotechnology R&D. Highest-conviction bullish signals stem from these full-and-open competition awards with options up to $481M for Shionogi and $114M for Vedanta, providing funding visibility amid $70M outlays already for Vedanta. The DLA Troop Support grant ($102M) adds neutral bulk but lacks revenue detail. Key watch item is Shionogi's $0 outlays to date and option exercises across both BARDA contracts, as no funds have flowed yet for the newest award.

3 total filings
· daily

New Federal Contractors — April 08, 2026

These 21 new federal contracts, aggregated at $1,703,423,541 total obligation over April 8, 2026, are entirely civilian with 0/21 defense-related, emphasizing HHS/BARDA biotech R&D, GSA/VA/State/Treasury IT services, and facilities support. Dominant agency themes include HHS ($198M+ across Shionogi and Vedanta), Treasury/IRS ($200M+ via two IBM awards), and VA ($219M+ via Salient CRGT, General Dynamics IT, Greenbrier). Highest-conviction bullish signal is Shionogi Inc's $119M HHS BARDA cost-plus-fixed-fee contract for biothreat antibiotics, with $481M potential over 10 years. Balanced by neutral/dated awards like Smartronix $116M GSA IT (2018-2023, negative outlays) and IBM $110M Treasury terminated in 2025. Key risk/watch: $0 outlays on 8 contracts (e.g., Shionogi, ManTech $77M), signaling near-term execution uncertainty amid CR risk for FY2026 awards.

21 total filings
· daily

Significant Contract Modifications ($10M+) — April 08, 2026

These 21 significant contract modifications totaling $1,703,423,541 in obligations are entirely civilian (0/21 defense-related), highlighting robust federal spending in biotech R&D, IT services, and facilities support outside DOD. Dominant themes include HHS/BARDA biothreat preparedness (Shionogi $119M, Vedanta $79M) and IT modernization across Treasury/IRS (IBM $110M + $90M), VA (Salient CRGT $93M), and GSA (Mantech $77M potential $910M). Highest-conviction bullish signal is Shionogi's $119M BARDA award (up to $482M options) for antibiotics R&D through 2036, signaling multi-year biotech revenue. Key risk is zero outlays on multiple high-value awards (e.g., Shionogi $119M, Mantech $77M, Deloitte $70M), exposing execution delays amid fixed-price structures.

21 total filings
· daily

Contract Deobligations Alert — April 08, 2026

This Contract Deobligations Alert covers 21 civilian contracts totaling $1,703,423,541 in obligations with 0 defense-related awards, highlighting robust civilian agency spending in HHS/BARDA biotech R&D and IT services across GSA, VA, Treasury/IRS, and State Department. Dominant sector themes include biothreat preparedness antibiotics (Shionogi $119M, Vedanta $79M) and multi-year IT modernization (Salient CRGT $93M VA, ManTech $77M GSA USSOUTHCOM cyber, IBM $90M Treasury). Highest-conviction bullish signal is Shionogi Inc's $119M HHS BARDA cost-plus-fixed-fee contract (potential $481M) for late-stage antibiotics R&D through 2036, signaling durable biotech revenue. Balanced by neutral signals on dated contracts like Smartronix's $116M GSA IT (negative -$162k outlays) and IBM's $110M terminated Treasury IT. Key risk is $0 outlays on 8 new/high-potential awards (e.g., ManTech $77M, Deloitte $70M), vulnerable to non-exercise amid CR uncertainty; watch outlay progression and option exercises for revenue conversion.

21 total filings
· daily

Contract Option Exercises — April 08, 2026

These 21 contract option exercises total $1,703,423,541 in obligations, entirely civilian agency awards with zero defense-related contracts, highlighting steady federal spending outside DOD amid a one-day snapshot from April 8, 2026. Dominant themes include HHS/BARDA biotech R&D for biothreat preparedness (e.g., Shionogi $119M, Vedanta $79M) and multi-agency IT modernization/services (IBM $200M+ across two Treasury awards, Salient CRGT $93M VA). Highest-conviction bullish signal is ManTech International's $77M GSA award (up to $910M ceiling) for USSOUTHCOM cyber IT, signaling long-term growth through 2032 despite $0 outlays to date. Key risk is execution uncertainty from $0 outlays on fresh awards like Shionogi and numerous firm-fixed-price structures exposing contractors to cost overruns.

21 total filings
· daily

Federal Professional Services Contracts — April 08, 2026

These four civilian federal professional services contracts total $346,731,554 in obligations, with zero defense-related awards, spanning Department of State, Pension Benefit Guaranty Corporation (PBGC), Department of Transportation (DOT)/Federal Railroad Administration (FRA), and Department of Homeland Security (DHS)/FEMA. The dominant theme is multi-year engineering and administrative support services under NAICS 541330 and related PSCs, with firm-fixed price structures introducing high execution risks. Highest-conviction signal is bullish for SERCO INC's $95.8M PBGC delivery order, where 58% ($55.7M) has already been outlayed shortly after award. Neutral signals dominate for the others due to limited outlays (e.g., $0 for Quality Support, Inc.) and option uncertainties. Key watch item: outlay progress and option exercises across all contracts, given high pricing risks and potential ceilings up to $599M combined.

4 total filings
· daily

All HHS Contracts — April 08, 2026

HHS awarded $300,921,779 across three contracts in this period, all civilian with 0/3 defense-related, dominated by BARDA's biothreat preparedness theme in biotech R&D for antibiotics targeting drug-resistant infections and pathogens. Highest-conviction bullish signals emerge from Shionogi Inc's $119M obligation (potential $481M) and Vedanta Biosciences' $79M obligation ($70M outlayed, potential $114M), providing multi-year revenue visibility in a non-competitive, full-and-open award environment. The neutral $103M grant to DLA Troop Support adds minimal investment signal due to its low materiality and unknown revenue impact. A key risk is Shionogi's $0 outlays to date and uncertain option exercises, warranting close monitoring of funding progress. Overall, this underscores civilian HHS growth in biodefense R&D, differentiating from DOD priorities.

3 total filings
· daily

Mega Contracts Monitor ($100M+) — April 08, 2026

These six civilian mega contracts total $661,042,003 in obligations, with 0/6 defense-related, spanning HHS, GSA, State, Treasury, and NASA. Dominant themes include HHS biothreat preparedness R&D and IT/administrative services, highlighted by Shionogi Inc's $119M BARDA award for antibiotics development. Highest-conviction bullish signal is Shionogi's long-term 10-year structure with $481M potential, alongside Syncom Space Services LLC's $100M NASA facilities support nearing full outlay. Key risk is pervasive $0 outlays across Shionogi ($119M), Quality Support Inc ($113M), and the HHS grant to DLA Troop Support ($103M), signaling execution delays. Watch dated contracts like Smartronix LLC's 2018-2023 GSA IT award with negative -$162k outlays and IBM's terminated Treasury deal.

6 total filings
· daily

High-Value Federal Grants ($5M+) — April 08, 2026

This digest synthesizes 20 high-value federal grants totaling $1,698,888,861 in obligations, all civilian agency awards with 0 defense-related contracts, highlighting steady civilian IT services and biotech R&D spending amid no DOD exposure. Dominant themes include HHS/BARDA biotech for biothreat preparedness ($198M across Shionogi $119M and Vedanta $79M) and multi-agency IT modernization (VA $219M across Salient $93M, GDIT $65M, Greenbrier $61M; Treasury/IRS $201M across two IBM awards $110M+$90M). Highest-conviction bullish signal is Salient CRGT's $93M VA IT delivery order (potential $199M) with $22M already outlayed, signaling strong execution in technical application platforms. Key risk is execution uncertainty from $0 outlays on fresh awards like Shionogi $119M, Mantech $77M (potential $910M for USSOUTHCOM cyber), and Deloitte $70M State IT, vulnerable to delays in funding release.

20 total filings
· daily

General Federal Contracts — April 08, 2026

This digest synthesizes 20 civilian federal contracts totaling $1,698,888,861 in obligations from April 08, 2026, with zero defense-related awards, highlighting steady civilian agency spending in biotech R&D and IT services. Dominant themes include HHS/BARDA biothreat preparedness (e.g., Shionogi Inc's $119M antibiotic development) and VA IT platforms (e.g., Salient CRGT's $93M technical application services), alongside GSA and Treasury IT modernization. Highest-conviction bullish signal is Shionogi Inc's $119M (potential $481M) BARDA cost-plus-fixed-fee contract for multi-year biotech R&D against drug-resistant pathogens, offering durable revenue visibility through 2036. Key risk is execution uncertainty from 10+ contracts with $0 outlays (e.g., ManTech's $77M USSOUTHCOM cyber IT) and dated awards like SMARTRONIX LLC's 2018-2023 GSA IT order showing negative -$162k outlays.

20 total filings
· daily

All NASA Contracts — April 08, 2026

NASA awarded two civilian contracts totaling $104,671,053 in obligations during the April 8, 2026 period, with zero defense-related activity out of two records. The dominant theme is NASA support for space R&D facilities and astrophysics technology maturation at Stennis and Marshall Space Flight Centers. The highest-conviction bullish signal stems from SYNCOM SPACE SERVICES LLC's (Amentum subsidiary) $100,136,373 facilities support contract at Stennis, with $98,511,670 already outlayed indicating strong execution nearing the June 30, 2025 completion. Lockheed Martin Corporation's smaller $4,534,680 TECHMAST contract adds neutral R&D exposure but carries high pricing risk. A key watch item is option exercises on both contracts to reach full ceilings of $102,711,387 for SYNCOM and $4,759,423 for Lockheed amid ongoing outlays.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 08, 2026

Filings reveal selective revenue acceleration in niche operators like ImmuCell (Q1 sales +28.4% YoY to $10.4M, domestic +35.7%) and GameSquare (FY2025 revenue +63% YoY to $45M, Agency segment +119%), offset by persistent net losses (GameSquare $42M improved from $54M; Portsmouth $9.1M from $13.2M) and international softness (ImmuCell -30.2%). IBM stands out with bullish 2025 metrics ($67.5B revenue, $13.2B operating cash, $6.3B shareholder returns including 30th consecutive dividend hike), signaling sustained tech growth into 2026. Proxy materials (IBM, Genco, Portsmouth) show stable governance with flat/mixed compensation and board recommendations against activist proposals. Institutional 13F discloses broad tech exposure (AAPL, AMZN) amid neutral sentiment. Overall mixed sentiment across filings highlights growth pockets in tech-adjacent plays but underscores operational risks and backorder drags; portfolio-level trend of narrowing losses amid revenue beats offers tactical opportunities ahead of May catalysts.

3 high priority 4 medium 7 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 08, 2026

Across the 7 NASDAQ-100 related filings, dominant themes include strategic asset consolidation (Intel's $14.2B JV buyout for full fab control), robust product sales growth in niche biotech (ImmuCell's Q1 2026 +28.4% YoY to $10.4M), institutional portfolio disclosures signaling sustained tech exposure (Community Financial's $568M holdings heavy in Apple/Amazon), proxy solicitations highlighting insider ownership changes (Genco's multiple 2025-2026 Form 4s), SPAC unit liquidity events (Metals Acquisition II separation April 14), speculative crypto ETF launches (Canary PEPE amid high volatility risks), and fund reorganizations (MFS CXE adjournment to April 8). Period-over-period trends show outlier strength in ImmuCell's domestic sales (+35.7% YoY to $9.7M, Tri-Shield +38.5%) contrasting international declines (-30.2%), with no broad margin or revenue compression patterns due to limited financials. Intel's move implies bullish capex commitment amid chip sector rivalry, financed via $6.5B bridge loan (refinance pending market conditions), while PEPE ETF flags extreme speculation risks from 2023's 3.8% supply dump. Portfolio-level implications favor monitoring manufacturing control and growth catalysts, with neutral sentiment dominating (4/7 filings) but high materiality in Intel (9/10) and PEPE (9/10). Actionable now: Favor Intel for supply chain alpha, caution on meme volatility.

3 high priority 4 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Financials stream, 13F-HR reports from asset managers (e.g., E Fund, Charis Legacy, Wisconsin Wealth) dominate with neutral sentiment, revealing heavy allocations to tech giants (Apple, Amazon, NVIDIA) and ETFs, signaling institutional conviction in broad market indices amid March 31, 2026 quarter-end. Financials-specific highlights include REIT strength at Kimco Realty (96.4% occupancy, 4% YoY dividend hike to $1.01/share, $248M acquisitions) and Corebridge Financial's transformative all-stock merger with Equitable Holdings targeting $1.5T AUM by YE 2026. Period-over-period trends show revenue growth in outliers like ATRenew (+28.9% YoY to $3B), Grown Rogue (+22% YoY), SmartKem (+750% YoY) but sharp declines in Nurix (-66% YoY revenue, net loss widened to $87M) and cash burn (SmartKem cash -95% to $374k). Capital allocation leans positive with dividends (Ellington $0.08/month, Vistance $10 special), buybacks (Kimco 6.1M shares, News Corp $1B program), and M&A momentum (Corebridge-Equitable, Day One tender at $21.50/share). Proxy-heavy calendar (May 2026 meetings) and merger catalysts signal near-term volatility, favoring patient capital in resilient REITs/financial consolidators over high-burn biotechs.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors), proxy statements dominate (17+ filings) signaling intense AGM season in May 2026, with boards pushing declassification, auditor ratifications, and say-on-pay votes amid stable governance. Earnings reports show mixed period-over-period trends: 9/18 quantifiable filings reported revenue growth averaging +20% YoY (e.g., Delta +13%, RPM +8.9%, ImmuCell +28.4%), but 4 saw sharp declines (Constellation -10%, Mobiquity -95%, Safe & Green dilution risks); margins improved in 4/10 (Richardson +110 bps to 31.9%, RPM EBIT +48.8%) but compressed elsewhere (Constellation Beer -170 bps). Capital allocation leans shareholder-friendly with $255M returns at RPM (+5.2% YoY), $1.6B at Constellation, and steady dividends (Ellington $0.08/share, Constellation +1% to $1.03); M&A active in tuck-ins (PMGC 4 deals, RPM Kalzip) and divestitures (Atkore HDPE sale). Forward guidance mixed: reaffirmations (RPM mid-single digits), raises (Delta low-teens Q2 revenue), cuts/withdrawals (Constellation FY28 outlook gone). Sentiment mixed/neutral overall (28/50), with portfolio-level theme of resilient sales growth masking consumer softness (RPM Consumer -2.4% organic). Implications: Favor dividend payers and M&A consolidators; watch May catalysts for guidance updates amid economic uncertainty.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Industrials stream, key themes include robust revenue growth in transportation and chemicals (e.g., Delta +9.4% YoY, RPM +8.9% YoY, Venture Global +177% YoY) offset by margin pressures and one-off losses (Delta op margin - to 3.2%, Regeneron $102M IPR&D charge). M&A activity surges with deals like Corebridge-Equitable all-stock merger (close YE2026), Day One tender at $21.50/share (antitrust cleared), and Catalyst Bancorp $41.1M acquisition (180% EPS accretive). Proxy season dominates with 15+ DEF/DEFA14A filings for May 2026 meetings, signaling governance focus amid neutral sentiment. 18 13F-HR filings reveal institutional stability in industrials/transports (e.g., CSX, H2O America) and ETFs, with no major shifts. Capital returns strong at RPM ($255M +5.2% YoY). Forward guidance mixed: RPM mid-single-digit Q4 sales, Delta low-teens June rev. Sector implications point to resilient demand but cost headwinds, with catalysts in Q2 earnings and meetings.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 08, 2026

Across 10 SEC filings from the S&P 500 Energy stream (with some adjacent sectors), overarching themes include robust shareholder engagement via proxy materials and AGMs, proactive capital returns through special distributions and dividend approvals, and neutral-to-positive sentiment amid earnings preparations and credit access, contrasted by risk disclosures in LNG shipping. No explicit period-over-period financial declines are noted, but XOM highlights leading 29% five-year total annualized shareholder returns among IOCs driven by Permian, Guyana, and LNG growth, signaling sector strength in upstream advantaged assets. Critical developments feature Vistance's $10/share special cash distribution (funded by asset sale, avoiding leverage amid volatility) and CommScope's $300M revolver, indicating liquidity bolstering; SLB's unanimous AGM approvals reflect governance confidence. Portfolio-level patterns show 4/10 filings positive (e.g., distributions, performance boasts), 1 negative (LNG risks), and 5 neutral (proxies, exhibits), with no YoY/QoQ deteriorations but forward catalysts like XOM's May 27 meeting and Vistance payment April 27. Market implications favor near-term yield plays and monitoring Middle East impacts on XOM operations.

4 high priority 6 medium 10 total filings
· daily

US Material Events SEC 8-K Filings — April 08, 2026

Across 43 filings from April 8, 2026, dominant themes include widespread executive transitions (17 instances, particularly CFO appointments/resignations in 9 cases), signaling strategic shifts amid sector pressures; robust M&A and financing activity (10 deals/facilities, including bank acquisitions doubling assets and $1.5B+ credit lines); and liquidity enhancements via credit extensions and equity raises without noted performance declines. No broad period-over-period revenue/margin declines reported, with accretive M&A (e.g., 180% EPS accretion) and positive forward guidance in biotech/energy standing out vs. neutral executive churn. Mixed sentiment in leadership losses (e.g., CEO passing) contrasts bullish capital raises and AI expansions, implying portfolio-level opportunities in banking consolidation and infrastructure plays. Critical implications: monitor transition risks in financials/tech, capitalize on accretive deals pre-Q3 closes. Aggregate capital allocation favors reinvestment (RSUs/bonuses) over buybacks/dividends, with no insider selling patterns detected.

43 high priority 43 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 08, 2026

Across 50 SEC filings from Dow Jones 30-related entities on April 8, 2026, dominant themes include a proxy season surge with 15+ DEF 14A/DEFA14A filings for May 2026 AGMs, robust M&A activity (e.g., Clearwater sale process, Kenvue-Kimberly-Clark merger, CECO-Thermon), and mixed financial trends: explosive energy growth (Venture Global revenue +177% YoY to $13.8B) offset by consumer/healthcare softness (Kenvue sales -2.1% YoY, Avalyn losses +71% YoY to $85.2M). Institutional 13F-HR filings (12 total) reveal persistent heavy allocations to tech giants (Apple, Amazon, NVIDIA across 8+ filers) and ETFs, signaling broad market conviction in megacaps amid volatility. Capital allocation leans shareholder-friendly with buybacks (Voya $300M in Q1/Q2 2026, Intel $14.2B JV repurchase), while operational wins like Brookdale occupancy +250bps YoY to 82.0% highlight recovery plays. Portfolio-level trends show margin resilience (Kenvue op margin +410bps to 16.0%) despite top-line pressures, with forward catalysts clustered in H2 2026 mergers and May AGMs. Overall, blue-chip stability persists, but M&A and energy outliers offer alpha amid Nasdaq compliance risks in small-caps.

18 high priority 32 medium 50 total filings